Aptevo Therapeutics Files 8-K
Ticker: APVO · Form: 8-K · Filed: Apr 29, 2025 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
Related Tickers: APVO
TL;DR
APVO filed an 8-K, check for updates.
AI Summary
Aptevo Therapeutics Inc. filed an 8-K on April 29, 2025, reporting other events and financial statements. The filing does not contain specific details on new events or financial figures within the provided text.
Why It Matters
This filing indicates Aptevo Therapeutics is making a regulatory submission, which could contain important updates for investors.
Risk Assessment
Risk Level: low — The filing is a routine regulatory disclosure and does not contain immediate negative or positive news.
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- April 29, 2025 (date) — Date of earliest event reported
- 206-838-0500 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Aptevo Therapeutics Inc.?
The filing is a Current Report on Form 8-K, intended to report "Other Events" and "Financial Statements and Exhibits" as of April 29, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is April 29, 2025.
What is the principal executive office address for Aptevo Therapeutics Inc.?
The principal executive offices are located at 2401 4th Avenue, Suite 1050, Seattle, Washington, 98121.
What is the Commission File Number for Aptevo Therapeutics Inc.?
The Commission File Number for Aptevo Therapeutics Inc. is 001-37746.
What is the Standard Industrial Classification code for Aptevo Therapeutics Inc.?
The Standard Industrial Classification code for Aptevo Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 29, 2025 regarding Aptevo Therapeutics Inc. (APVO).